

**ASX Announcement | 13 September 2024**  
**Visioneering Technologies (ASX:VTI)**

## **VTI Announces Executive Changes**

**Atlanta, Georgia, USA:** US-based medical device company and producer of the NaturalVue® Multifocal 1 Day Contact Lenses, [Visioneering Technologies, Inc \(ASX:VTI\)](#) ('Visioneering', 'VTI' or 'the Company') today announced the appointment of Jeff Pruett as Vice President, Finance effective 19 September 2024 and the departure of COO & CFO Brian Lane following a transition period ending on November 15, 2024.

Mr. Pruett brings over 30 years of financial leadership to VTI. After starting his career with KPMG LLP, Jeff progressed through an impressive career in Finance. Prior to joining VTI, Jeff was the CFO and Treasurer of TechPro Power Group, a private equity-owned testing and inspection company where he was heavily involved in the operations of the company and worked closely with its lenders to ensure financial compliance. He held a similar role at Industrial Inspection and Analysis, another private equity-owned testing and inspection company. Jeff also held CFO and financial leadership roles in several global manufacturing, consulting and professional services companies including a publicly held healthcare services and technology manufacturing company.

Jeff holds a Bachelor of Business Administration, Accounting degree from Georgia State University and is a Certified Public Accountant (inactive).

**On behalf of the Board of Directors, Visioneering's CEO and Executive Director Dr. Juan Carlos Aragón, said:**

*"We are pleased to have Jeff join the VTI team to help lead the Company through the next phase of its growth. Jeff brings a wealth of financial experience across a variety of industries. With his track record of developing high performing teams and business development experience, we feel that Jeff will help accelerate our operational plans. We are grateful for the contribution Brian Lane has made to the company over the past six years and wish him well in his future endeavors. We look forward to Brian's involvement and support as Jeff transitions into his new role."*

**Ends**

**This release was authorized by the CEO and Executive Director, Dr. Juan Carlos Aragón.**

**For more information, please contact:**

<b>Company</b>	<b>Investor and media relations</b>
Brian Lane COO and CFO, Visioneering Technologies, Inc. Email: <a href="mailto:blane@vtivision.com">blane@vtivision.com</a>	Haley Chartres H^CK Tel: +61 423 139 163 Email: <a href="mailto:haley@hck.digital">haley@hck.digital</a>

## About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Multifocal 1-Day Contact Lens, an extended depth of focus lens that is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit [www.vtivision.com](http://www.vtivision.com) or call +1 844-884-5367, ext. 104.

## Foreign ownership restrictions

VTI's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers that are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

## Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX99